Cargando…
Novel doses of sacubitril/valsartan in patients unable to tolerate traditional therapy: Effects on N‐terminal pro B‐type natriuretic peptide levels
BACKGROUND: Widespread use of angiotensin receptor blocker and neprilysin inhibitor (ARNI) remains low, and many patients are unable to tolerate the medication due to hypotension at the currently recommended starting dose. HYPOTHESIS: The aim of this study is to assess if lower than standard doses o...
Autores principales: | Pandey, Amitabh C., Jer, Derek, Kuo, Ruth S., Yoo, David H., Christophy, Antonio, Mohan, Rajeev C., Srivastava, Ajay V., Heywood, James Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wiley Periodicals, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7803354/ https://www.ncbi.nlm.nih.gov/pubmed/33277928 http://dx.doi.org/10.1002/clc.23509 |
Ejemplares similares
-
Re: Implication of low‐dose sacubitril/valsartan
por: Pandey, Amitabh C., et al.
Publicado: (2021) -
The evolution of natriuretic peptide augmentation in management of heart failure and the role of sacubitril/valsartan
por: Yandrapalli, Srikanth, et al.
Publicado: (2017) -
Sacubitril/Valsartan Conundrum
por: Somberg, John
Publicado: (2021) -
Effect of sacubitril/valsartan on brain natriuretic peptide level and prognosis of acute cerebral infarction
por: Shen, Xiaozhu, et al.
Publicado: (2023) -
Effects of switching from sacubitril/valsartan to valsartan alone on plasma levels of natriuretic peptides and myocardial remodeling in heart failure with reduced ejection fraction
por: Nakamura, Akihiro, et al.
Publicado: (2023)